Scepter

Scepter is a clinical-stage immuno-oncology company focused on developing a novel class of cell therapies for the treatment of solid tumors. The company's proprietary platform is designed to engineer T cells that can effectively target and eliminate cancer cells while overcoming the immunosuppressive environment of the tumor microenvironment. Scepter's lead program, SC-101, is a CAR-T cell therapy currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors expressing specific oncogenic markers. By leveraging advanced genetic engineering and immunology, Scepter aims to provide durable clinical responses for patients with high unmet medical needs in oncology.